Abouyannis M.Esmail H.Hamaluba M.Ngama M.Mwangudzah H.Mumba N.Yeri B.K.Mwalukore S.Alphan H.J.Aggarwal D.Alcoba G.Cammack N.Chippaux J.P.Coldiron M.E.Gutiérrez J.M.Habib A.G.Harrison R.A.Isbister G.K.Lavonas E.J.Martins D.Ribeiro I.Watson J.A.Williams D.J.Casewell N.R.Walker S.A.Lalloo D.G.Mahidol University2024-02-082024-02-082023-09-30Medecine tropicale et sante internationale Vol.3 No.3 (2023)https://repository.li.mahidol.ac.th/handle/20.500.14594/95646Background: Snakebite clinical trials have often used heterogeneous outcome measures and there is an urgent need for standardisation. Method: A globally representative group of key stakeholders came together to reach consensus on a globally relevant set of core outcome measurements. Outcome domains and outcome measurement instruments were identified through searching the literature and a systematic review of snakebite clinical trials. Outcome domains were shortlisted by use of a questionnaire and consensus was reached among stakeholders and the patient group through facilitated discussions and voting. Results: Five universal core outcome measures should be included in all future snakebite clinical trials: mortality, WHO disability assessment scale, patient-specific functional scale, acute allergic reaction by Brown criteria, and serum sickness by formal criteria. Additional syndrome-specific core outcome measures should be used depending on the biting species. Conclusion: This core outcome measurement set provides global standardisation, supports the priorities of patients and clinicians, enables meta-analysis, and is appropriate for use in low-income and middle-income settings.MedicineArticleSCOPUS10.48327/mtsi.v3i3.2023.4212-s2.0-851797733552778203438094484